Dataset Information

Cross-Linguistic Data Formats, advancing data sharing and re-use in comparative linguistics.

ABSTRACT: The amount of available digital data for the languages of the world is constantly increasing. Unfortunately, most of the digital data are provided in a large variety of formats and therefore not amenable for comparison and re-use. The Cross-Linguistic Data Formats initiative proposes new standards for two basic types of data in historical and typological language comparison (word lists, structural datasets) and a framework to incorporate more data types (e.g. parallel texts, and dictionaries). The new specification for cross-linguistic data formats comes along with a software package for validation and manipulation, a basic ontology which links to more general frameworks, and usage examples of best practices.

SUBMITTER: Forkel R

PROVIDER: S-EPMC6190742 | biostudies-other | 2018 Oct

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Cross-Linguistic Data Formats, advancing data sharing and re-use in comparative linguistics.

Forkel Robert R List Johann-Mattis JM Greenhill Simon J SJ Rzymski Christoph C Bank Sebastian S Cysouw Michael M Hammarström Harald H Haspelmath Martin M Kaiping Gereon A GA Gray Russell D RD

Scientific data 20181016

The amount of available digital data for the languages of the world is constantly increasing. Unfortunately, most of the digital data are provided in a large variety of formats and therefore not amenable for comparison and re-use. The Cross-Linguistic Data Formats initiative proposes new standards for two basic types of data in historical and typological language comparison (word lists, structural datasets) and a framework to incorporate more data types (e.g. parallel texts, and dictionaries). T ...[more]

PMID: 30325347

Similar Datasets

Project description:BackgroundRecently, various evolution-related journals adopted policies to encourage or require archiving of phylogenetic trees and associated data. Such attention to practices that promote sharing of data reflects rapidly improving information technology, and rapidly expanding potential to use this technology to aggregate and link data from previously published research. Nevertheless, little is known about current practices, or best practices, for publishing trees and associated data so as to promote re-use.FindingsHere we summarize results of an ongoing analysis of current practices for archiving phylogenetic trees and associated data, current practices of re-use, and current barriers to re-use. We find that the technical infrastructure is available to support rudimentary archiving, but the frequency of archiving is low. Currently, most phylogenetic knowledge is not easily re-used due to a lack of archiving, lack of awareness of best practices, and lack of community-wide standards for formatting data, naming entities, and annotating data. Most attempts at data re-use seem to end in disappointment. Nevertheless, we find many positive examples of data re-use, particularly those that involve customized species trees generated by grafting to, and pruning from, a much larger tree.ConclusionsThe technologies and practices that facilitate data re-use can catalyze synthetic and integrative research. However, success will require engagement from various stakeholders including individual scientists who produce or consume shareable data, publishers, policy-makers, technology developers and resource-providers. The critical challenges for facilitating re-use of phylogenetic trees and associated data, we suggest, include: a broader commitment to public archiving; more extensive use of globally meaningful identifiers; development of user-friendly technology for annotating, submitting, searching, and retrieving data and their metadata; and development of a minimum reporting standard (MIAPA) indicating which kinds of data and metadata are most important for a re-useable phylogenetic record.

Project description:BackgroundTransparency and reproducibility are expected to be normative practices in clinical trials used for decision-making on marketing authorisations for new medicines. This registered report introduces a cross-sectional study aiming to assess inferential reproducibility for main trials assessed by the European Medicines Agency.MethodsTwo researchers independently identified all studies on new medicines, biosimilars and orphan medicines given approval by the European Commission between January 2017 and December 2019, categorised as 'main studies' in the European Public Assessment Reports (EPARs). Sixty-two of these studies were randomly sampled. One researcher retrieved the individual patient data (IPD) for these studies and prepared a dossier for each study, containing the IPD, the protocol and information on the conduct of the study. A second researcher who had no access to study reports used the dossier to run an independent re-analysis of each trial. All results of these re-analyses were reported in terms of each study's conclusions, p-values, effect sizes and changes from the initial protocol. A team of two researchers not involved in the re-analysis compared results of the re-analyses with published results of the trial.ResultsTwo hundred ninety-two main studies in 173 EPARs were identified. Among the 62 studies randomly sampled, we received IPD for 10 trials. The median number of days between data request and data receipt was 253 [interquartile range 182-469]. For these ten trials, we identified 23 distinct primary outcomes for which the conclusions were reproduced in all re-analyses. Therefore, 10/62 trials (16% [95% confidence interval 8% to 28%]) were reproduced, as the 52 studies without available data were considered non-reproducible. There was no change from the original study protocol regarding the primary outcome in any of these ten studies. Spin was observed in the report of one study.ConclusionsDespite their results supporting decisions that affect millions of people's health across the European Union, most main studies used in EPARs lack transparency and their results are not reproducible for external researchers. Re-analyses of the few trials with available data showed very good inferential reproducibility.Trial registrationhttps://osf.io/mcw3t/.

Dataset Information

Cross-Linguistic Data Formats, advancing data sharing and re-use in comparative linguistics.

Publications

Cross-Linguistic Data Formats, advancing data sharing and re-use in comparative linguistics.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets